Private Market View

Aifang Biotechnology

Changsha, China · Founded 2020 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Xingxiang Investment Holding Group.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Aifang Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Aifang Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Aifang Biotechnology

Developer of biotechnology products designed to advance health and life sciences research and innovation. The company offers cutting-edge biological reagents, advanced molecular and cellular technologies, and robust research tools, enabling scientific researchers and pharmaceutical developers to accelerate discovery and improve experimental accuracy.

Sector
Healthcare
HQ
Changsha, China
Founded
2020
Ownership
Privately Held (backing)
PA Mark — not yet priced

Aifang Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Aifang Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Aifang Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.